Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9665309 | 0.89 | CA2 (0.39) | CA2ALDH1A1LMNAKDM4ECA5A | |
| Sulfuric Acid SCHEMBL5770370 | 0.88 | CA5A (0.50) | CA2ALDH1A1LMNAKDM4ECA5A | |
| SCHEMBL575531 | 0.88 | CA2 (0.44) | CA2ALDH1A1LMNAKDM4ECA5A | |
| Isopropyl Alcohol SCHEMBL9431191 | 0.88 | — | — | |
| SCHEMBL28243588 | 0.84 | — | — | |
| SCHEMBL17908556 | 0.83 | CA2 (0.54) | CA2ALDH1A1KDM4ECA5ACA5B | |
| SCHEMBL756085 | 0.83 | — | — | |
| SCHEMBL11137444 | 0.83 | TP53 (0.36) | CA2ALDH1A1LMNAKDM4ECA5A | |
| SCHEMBL28072932 | 0.81 | — | — | |
| SCHEMBL1833267 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108140895-B | Nonaqueous electrolyte solution for lithium secondary battery or lithium ion capacitor, and lithium secondary battery or lithium ion capacitor using same | MU电解液株式会社 | 2021-04-30 | — | — | CN | disclosed |
| US-9708245-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9085527-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8846972-B2 | — | — | 2014-09-30 | — | — | US | disclosed |
| EP-1772924-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7629085-B2 | sulfur-containing acid ester and an alkyne-containing compound; excellent battery characteristics in cycle performance, electric capacity and storage property; e.g. 2-propynyl methyl carbonate and 1,3-propanesultone | UBE INDUSTRIES, LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20070231707-A1 | Nonaqueous Electrolytic Solution and Lithium Secondary Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1772924-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-6436582-B1 | A NON-AQUEOUS SOLVENT AND (II) AN ELECTROLYTE SALT DISSOLVED THEREIN AND (III) A DISULFONATE ESTER DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | FADS1, FASN, ALOX5 | CA2 1879/4885ALDH1A1 230/4885LMNA 3266/4885 |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | FADS1, FASN, ALOX5 | CA2 1879/4885ALDH1A1 230/4885LMNA 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.